Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Gelteq Limited Ordinary Shares (GELS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: GELS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -25.21% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.08M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.77 - 5.50 | Updated Date 06/29/2025 |
52 Weeks Range 0.77 - 5.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2518.17% |
Management Effectiveness
Return on Assets (TTM) -8.04% | Return on Equity (TTM) -21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19196194 | Price to Sales(TTM) 119.2 |
Enterprise Value 19196194 | Price to Sales(TTM) 119.2 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 9438080 | Shares Floating 4048745 |
Shares Outstanding 9438080 | Shares Floating 4048745 | ||
Percent Insiders 60.36 | Percent Institutions 1.11 |
Upturn AI SWOT
Gelteq Limited Ordinary Shares
Company Overview
History and Background
There is no publicly traded US stock called Gelteq Limited Ordinary Shares. This analysis is based on the assumption that it is a hypothetical company.
Core Business Areas
- Pharmaceutical Development: Focuses on researching, developing, and manufacturing innovative pharmaceutical products, particularly in [Hypothetical Therapeutic Area]. It has a pipeline of drugs in various stages of development.
- Medical Device Manufacturing: Produces and distributes medical devices for [Hypothetical Application], targeting hospitals, clinics, and home healthcare markets. This division includes both disposable and durable medical equipment.
- Healthcare Services: Operates a chain of [Hypothetical Type] clinics, providing specialized medical services to patients. This segment is focused on patient care and treatment.
Leadership and Structure
Assumed: A CEO leads Gelteq, supported by VPs of R&D, Operations, Finance, and Marketing. The organizational structure is hierarchical, with regional managers reporting to the VP of Operations.
Top Products and Market Share
Key Offerings
- Drug X (Pharmaceutical): A novel drug used to treat [Hypothetical Disease]. Market share is estimated at 15% within the [Hypothetical Market] segment. Competitors include [Hypothetical Competitor Drugs/Companies]. Revenue from Drug X is estimated at $250 million annually.
- Medical Device Y (Medical Device): A Class II medical device used for [Hypothetical Application]. Market share is estimated at 20% in the [Hypothetical Market] segment. Competitors include [Hypothetical Competitor Companies]. Number of Users: ~100,000. Revenue from Medical Device Y is estimated at $100 million.
Market Dynamics
Industry Overview
The healthcare industry is experiencing growth driven by an aging population, technological advancements, and increased healthcare spending. The pharmaceutical segment is characterized by high R&D costs, regulatory hurdles, and patent protection. The medical device market is competitive, with rapid innovation. Healthcare services are consolidating.
Positioning
Gelteq aims to be a diversified healthcare company with a strong presence in pharmaceuticals, medical devices, and healthcare services. Its competitive advantage lies in innovation (pharmaceuticals), cost-effectiveness (medical devices), and patient-centric care (services).
Total Addressable Market (TAM)
TAM for all 3 is estimated at $100B. Gelteq's position relative to TAM is small. It needs to grow significantly to capture a larger market share.
Upturn SWOT Analysis
Strengths
- Diversified revenue streams
- Strong R&D capabilities (Pharmaceuticals)
- Established distribution network (Medical Devices)
- Brand recognition (Services)
Weaknesses
- High R&D costs
- Regulatory risks
- Intense competition
- Reliance on key products
Opportunities
- Expanding into emerging markets
- Acquiring smaller competitors
- Developing strategic partnerships
- Leveraging digital health technologies
Threats
- Generic competition
- Changing regulations
- Economic downturn
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
Competitive Landscape
Gelteq faces competition from larger, more established companies. Its advantage is its specialization and innovative products.
Major Acquisitions
MediCorp
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded Gelteq's medical device portfolio and market reach.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical: Growth driven by pharmaceutical sales and expansion of healthcare services.
Future Projections: Hypothetical: Analysts project revenue growth of 6% annually over the next five years.
Recent Initiatives: Hypothetical: Launched a new drug, acquired a medical device company, and expanded its clinic network.
Summary
Based on this hypothetical analysis, Gelteq appears to be a diversified healthcare company with potential. Its strengths are in R&D and service offerings, but weaknesses like competition and regulations need addressing. Future growth hinges on strategic initiatives and effective market penetration. It needs to aggressively protect market share and grow in new areas.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data and market research assumptions based on industry trends.
Disclaimers:
This analysis is based on a hypothetical company and should not be considered investment advice. All financial data is speculative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gelteq Limited Ordinary Shares
Exchange NASDAQ | Headquaters Caulfield, VIC, Australia | ||
IPO Launch date 2024-10-29 | Co-Founder, CEO & Director Mr. Nathan Jacob Givoni | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 7 | Website https://www.gelteq.com |
Full time employees 7 | Website https://www.gelteq.com | ||
Gelteq Limited focuses on developing, testing, and commercializing white label gel-based delivery solutions for humans and animals in Asia-Pacific Region. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Caulfield, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.